These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32723974)

  • 1. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
    Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
    Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
    Liu Z; Lin G; Yan Z; Li L; Wu X; Shi J; He J; Zhao L; Liang H; Wang W
    Front Immunol; 2022; 13():989275. PubMed ID: 36238300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
    Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
    J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Meng G; Liu X; Ma T; Lv D; Sun G
    PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
    Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
    Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer.
    Cai L; Bai H; Duan J; Wang Z; Gao S; Wang D; Wang S; Jiang J; Han J; Tian Y; Zhang X; Ye H; Li M; Huang B; He J; Wang J
    J Immunother Cancer; 2019 Jul; 7(1):198. PubMed ID: 31349879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
    Zhao X; Yang M; Fan J; Wang M; Wang Y; Qin N; Zhu M; Jiang Y; Gorlova OY; Gorlov IP; Albanes D; Lam S; Tardón A; Chen C; Goodman GE; Bojesen SE; Landi MT; Johansson M; Risch A; Wichmann HE; Bickeböller H; Christiani DC; Rennert G; Arnold SM; Brennan P; Field JK; Shete S; Le Marchand L; Liu G; Hung RJ; Andrew AS; Kiemeney LA; Zienolddiny S; Grankvist K; Johansson M; Caporaso NE; Woll PJ; Lazarus P; Schabath MB; Aldrich MC; Patel AV; Davies MPA; Ma H; Jin G; Hu Z; Amos CI; Shen H; Dai J
    Cancer; 2024 Mar; 130(6):913-926. PubMed ID: 38055287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data.
    Wang Y; Wang Y; Wang Y; Zhang Y
    Sci Rep; 2020 May; 10(1):8575. PubMed ID: 32444802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation markers of early-stage non-small cell lung cancer.
    Lokk K; Vooder T; Kolde R; Välk K; Võsa U; Roosipuu R; Milani L; Fischer K; Koltsina M; Urgard E; Annilo T; Metspalu A; Tõnisson N
    PLoS One; 2012; 7(6):e39813. PubMed ID: 22768131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
    Li X; Wang R; Wang S; Wang L; Yu J
    Front Immunol; 2022; 13():989968. PubMed ID: 36389757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
    Li C; Pan J; Luo J; Chen X
    BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
    Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
    Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.
    Xu D; Li J; Wang D; Zhou L; Jin J; Wang Y
    Crit Rev Oncol Hematol; 2022 Jan; 169():103573. PubMed ID: 34933103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
    Pan D; Hu AY; Antonia SJ; Li CY
    J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.